Neuroprotective effects of luteolin against apoptosis induced by 6-hydroxy dopamine on rat pheochromocytoma PC12 cells

Document Type

Journal Article

Publication Date

2013

Keywords

Flavonoid, Parkinson’s disease, Neurodegenerative, Bax, Bcl-2, p53

DOI

10.3109/13880209.2012.716852

Abstract

Context: Apoptotic neuronal cell death plays an important role in Parkinson’s disease (PD), a progressive neurodegenerative disorder. Luteolin, a flavonoid, has been shown to possess various pharmacological properties including strong antioxidant capacity.

Objective: This study investigated the neuroprotective effect of luteolin against cytotoxicity induced by 6-hydroxy-dopamine (6-OHDA) (250 µM) in rat pheochromocytoma (PC12) cell line.

Materials and Methods: The neuroprotective effect of luteolin against 6-OHDA-induced cytotoxicity in PC12 was evaluated by using cell viability test, nuclear staining and flow cytometry. In addition, the apoptotic role of luteolin was unveiled by monitoring mRNA expression of proapoptotic and anti-apoptotic genes.

Results: Pretreatment with luteolin (3.13, 6.25, 12.5, 25 or 50 µM) could markedly attenuate 6-OHDA-induced PC12 cell viability loss in a concentration-dependent manner. Cell morphologic analysis and nuclear staining assays showed that luteolin (3.13, 12.5 or 50 µM) protected the cells from 6-OHDA-induced damage. As shown in the flow cytometry assay, the increased apoptotic rate induced by 6-OHDA could be significantly (p < 0.001) suppressed by luteolin (12.5 or 50 µM) pretreatment. The protection of luteolin (50 µM) against 6-OHDA-induced cell damage was shown to be through suppressing the over-expression of Bax gene (p < 0.01), inhibiting the reduction of Bcl-2 gene expression (p < 0.05) and markedly depressing the enhanced Bax/Bcl-2 ratio. Luteolin also downregulated the gene expression level of p53.

Discussion and Conclusion: Luteolin has protective effects against 6-OHDA-induced cell apoptosis and might be a potential nutritional supplement which could be used to prevent neurodegenerative diseases such as PD.

Source Publication

Pharmaceutical Biology

Volume Number

51

Issue Number

2

First Page

190

Last Page

196

This document is currently not available here.

Link to Publisher’s Version

Share

COinS